NeuroControl
This article was originally published in The Gray Sheet
Executive Summary
Firm receives humanitarian use designation for its Vocare bladder system, which is intended for individuals with complete spinal cord injuries. Vocare uses functional electrical stimulation technology to deliver electrical impulses to nerve roots leading to bladder and bowel muscles, helping those with complete spinal cord injuries to control the loss of bladder and bowel functions. Since the commencement of clinical trials in mid-1996 ("The Gray Sheet" May 13, 1996, I&W-5), twenty-six people have been implanted with the device, the firm says. NeuroControl estimates approximately 73,000 people in the U.S. could potentially benefit from the product...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.